New treatment approach for difficult-to-surgically-remove pancreatic cancer
Official title: Total Neoadjuvant Therapy (TNT) for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Funded at Sloan-Kettering Inst Can Research · NIH-10908415 · Data updated 2026-11-12
This study is looking at a new way to treat patients with tough-to-reach pancreatic cancer by giving them chemotherapy and radiation before surgery to help shrink the tumors and make surgery more successful.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 20, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $647,018 |
| NIH project number | 5P50CA257881-03 |
| Project ID | NIH-10908415 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with borderline resectable or locally advanced pancreatic adenocarcinoma who have not yet undergone surgery.
✕Less likely to help
Patients with early-stage pancreatic cancer who are already eligible for surgery may not benefit from this research.
What this research studies
This research investigates a new treatment strategy called total neoadjuvant therapy (TNT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma. The approach involves administering a combination of chemotherapy and radiotherapy before surgery to shrink tumors and improve surgical outcomes. By evaluating the effectiveness of a specific chemotherapy regimen, the study aims to identify which patients are most likely to benefit from surgery and to personalize treatment plans based on individual responses. This comprehensive evaluation seeks to enhance the chances of successful tumor removal and improve overall patient outcomes.
Why it matters
Potential benefit: If successful, this research could significantly increase the number of patients eligible for curative surgery and improve survival rates for those with advanced pancreatic cancer.
How similar studies have gone: Previous research has shown promising results with neoadjuvant therapy approaches in similar patient populations, indicating potential for success with this novel treatment strategy.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Wei, Alice Chia- Chi — Sloan-Kettering Inst Can Research
- Study coordinator: Wei, Alice Chia- Chi
Related research
Other NIH-funded projects on the same topics.
-
Total Neoadjuvant Therapy for Borderline or Locally Advanced Pancreatic Cancer
A multi-part treatment approach tests giving all chemotherapy and targeted radiotherapy before surgery to help patients with tough-to-remove pancreatic cancer become eligible for curative surgery.
-
Intensive pre-surgery treatment for borderline and locally advanced pancreatic cancer
This gives strong combination chemotherapy followed by high-dose targeted radiation before surgery for people with borderline resectable or locally advanced pancreatic cancer to shrink tumors and make surgery possible.
-
PASSCODE: Coordinating and Sharing PDAC stromal research data
A networked effort at NYU School of Medicine aims to study how the pancreatic cancer stroma shapes tumor growth and patient outcomes, by coordinating researchers, sharing data, and educating the field.
-
Oncostatin M Receptor in Pancreatic Cancer
Aims to understand how a molecule called Oncostatin M and its receptor affect pancreatic cancer to find new ways to help patients.
-
Low-dose, motion-aware MRI to study pancreatic cancer
A new MRI method using low-dose contrast and motion-resolved imaging is being explored to better characterize pancreatic cancer in patients.
-
SOAT1 as a target in pancreatic cancer
Researchers are studying a specific enzyme, SOAT1, to see if blocking it can slow down or stop pancreatic cancer progression in models that mimic human disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.